These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 16392893

  • 1. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE, Keating GM.
    BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
    [Abstract] [Full Text] [Related]

  • 2. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J.
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R, Cerea G, Schiavetto I, Maugeri MR, Pedrazzoli P, Siena S.
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J.
    Drugs; 2002 Dec; 62 Suppl 1():89-98. PubMed ID: 12479597
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
    Yang BB, Savin MA, Green M.
    Chemotherapy; 2012 Dec; 58(5):387-98. PubMed ID: 23296266
    [Abstract] [Full Text] [Related]

  • 13. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB, Kido A.
    Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
    [Abstract] [Full Text] [Related]

  • 16. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [Abstract] [Full Text] [Related]

  • 17. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC.
    J Clin Oncol; 2003 Feb 01; 21(3):514-9. PubMed ID: 12560443
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
    Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C.
    J Pediatr Hematol Oncol; 2005 Aug 01; 27(8):449-51. PubMed ID: 16096530
    [Abstract] [Full Text] [Related]

  • 20. An analysis of current neutropenia therapies, including pegfilgrastim.
    Gabrilove JL.
    Clin Cornerstone; 2006 Aug 01; 8 Suppl 5():S19-28. PubMed ID: 17379160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.